Aptorum Group Limited is a clinical-stage biopharmaceutical company engaged in discovering and developing therapeutic products for oncology and infectious diseases. The company's pipeline consists primarily of repurposed drug candidates and novel small molecules in various stages of preclinical and early clinical development. Its oncology program includes SACT-1, currently in phase 1 trials for neuroblastoma and other cancer types, alongside preclinical candidates SACT-2, SACT-3, and DLS-1+2 targeting non-small cell lung cancer with specific mutations. The infectious disease portfolio comprises ALS-4, in phase 1 development for bacterial infections including drug-resistant strains, along with preclinical programs ALS-1, ALS-2/3, and SACT-COV19 addressing various bacterial and viral pathogens.
Beyond its core pipeline, the company is developing candidates for additional therapeutic areas including endometriosis (NLS-1), autoimmune disease (DLS-3), and obesity (CLS-1). Aptorum also offers NativusWell DOI, a dietary supplement for menopausal women, and provides management services. The company operates as a minimal-scale organization with a single full-time employee on staff, maintaining headquarters in London, United Kingdom while incorporated in the Cayman Islands. The company was previously known as APTUS Holdings Limited before rebranding to Aptorum Group Limited in October 2017.
No 10-K filings found.